Back to top

AveXis (AVXS) Enters Overbought Territory

Read MoreHide Full Article

AveXis, Inc. has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because AVXS is now in overbought territory with an RSI value of 84.43.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet AVXS’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in AveXis’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of AVXS’s prospects for the near term.

Over the past one month, investors have witnessed 5 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for AVXS has also been on a downward trend over the same time period too, as the estimate has fallen from -$5.76/share two months ago to just -$7.63/share today.

If this wasn’t enough, AveXis also has a Zacks Rank #4 (Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.     

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.  

See the pot trades we're targeting>>                                     




Normally $25 each - click below to receive one report FREE:


More from Zacks Tale of the Tape

You May Like